Rights issues have a way of humbling even the most celebrated founders. Fidelis Ayebae's Fidson Healthcare closed its N21 billion rights issue 117 percent oversubscribed in early 2026, pulling in N24.65 billion in valid applications against N21 billion on offer. It was a ringing market verdict on three decades of pharmaceutical conviction. The price of success, it turns out, is dilution.